Source document or public record

FDA 510(k) K202755 — Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack

FDA 510(k) index record K202755. Device: Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack. Applicant as listed: Diasorin Molecular, LLC. Decision date: 2022-11-05.

OtherU.S. Food and Drug Administration (FDA)2022-11-05

Source

"device_name": "Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack"

This entry describes what the document covers; the document itself is the authority. Listing it is not agreement with its conclusions.

Review and references

Reviewer

Automated FDA record verification

Published

2026-10-20

Updated

2026-10-20

Disclaimer

professional use

FDA 510(k) public index record K202755.

Device name: Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack. Applicant as listed: Diasorin Molecular, LLC.

Decision date: 2022-11-05. Decision wording: Substantially Equivalent.

Product code: QDZ. Regulation: 21 CFR 866.3181. Medical specialty: Microbiology.

This page reproduces regulator index metadata. The applicant field identifies the submitter and is not a manufacturer identity check. Consult the original FDA record for the decision and associated documents; this index does not verify current commercial availability or clinical performance.

Interested in these solutions?

Submit a sourcing request with the assays, volumes, and timeline of your own project.

FDA 510(k) K202755 — Simplexa Congenital CMV Direct and Simplexa Congenital CMV Positive Control Pack | Case Studies